Global Lung Cancer Diagnostic Tests Market Size By Type (Immunoassays, Flow Cytometry), By Application (Precision Medicine, Personalized Medicine), By Region, And Segment Forecasts, 2023 to 2032

The Global Lung Cancer Diagnostic Tests Market was valued at USD 2.9 billion in 2023 and is projected to reach USD 6.1 billion by 2031, growing at a CAGR of 9.7% during the forecast period from 2023 to 2031. The rising prevalence of lung cancer worldwide, increasing awareness of early detection, and growing adoption of advanced diagnostic technologies are key drivers of market growth. In particular, the shift toward minimally invasive procedures and liquid biopsies is transforming the diagnostic landscape and enhancing the accuracy and speed of diagnosis, leading to better patient outcomes.

Drivers:

1. Rising Incidence of Lung Cancer:

The increasing global incidence of lung cancer, driven by smoking, pollution, and genetic factors, is boosting demand for early and accurate diagnostic solutions. Timely diagnosis significantly improves prognosis, making diagnostics essential in cancer care pathways.

2. Technological Advancements in Diagnostics:

Innovations in molecular diagnostics, imaging techniques, and AI-based tools are elevating the accuracy, speed, and reliability of lung cancer detection. Tools such as low-dose computed tomography (LDCT), PET-CT, and next-generation sequencing (NGS) are enhancing the diagnostic process.

3. Shift Toward Personalized Medicine:

The growing emphasis on targeted therapies and personalized medicine is increasing the demand for biomarker-based lung cancer tests. Diagnostics are now essential for identifying mutations like EGFR, ALK, and PD-L1 that guide therapy selection.

Restraints:

1. High Cost of Diagnostic Tests:

Advanced diagnostics such as NGS and PET-CT can be expensive, limiting access in low- and middle-income countries. Lack of insurance coverage and reimbursement policies in some regions further hinder widespread adoption.

2. Limited Awareness and Access in Developing Regions:

Inadequate healthcare infrastructure, limited awareness, and insufficient screening programs in developing countries are key challenges to the growth of the global market.

Opportunity:

1. Expansion of Liquid Biopsy and AI-Based Diagnostics:

Non-invasive diagnostic approaches like liquid biopsies are rapidly gaining traction. Additionally, AI-driven diagnostic systems are enabling faster image analysis, early-stage detection, and more precise assessments, opening up significant market potential.

2. Public-Private Partnerships for Early Cancer Detection:

Growing collaborations between governments, non-profit organizations, and private companies are supporting national screening programs and awareness campaigns, especially in high-risk populations.

Market by System Type Insights:

By system type, imaging tests (such as LDCT and PET-CT) held the largest market share in 2023 due to their widespread use in screening and staging. However, molecular diagnostic tests are expected to grow at the fastest rate, driven by increasing use in precision oncology and targeted therapy selection.

Market by End-use Insights:

The hospitals and diagnostic laboratories segment emerged as the largest end-use category, accounting for over 60% of market share in 2023. This is attributed to the availability of advanced diagnostic tools, trained personnel, and high patient footfall. Meanwhile, the homecare and research settings segment is expected to grow steadily due to the rising demand for at-home testing kits and clinical trials focusing on biomarker development.

Market by Regional Insights:

North America dominated the global lung cancer diagnostic tests market in 2023, driven by advanced healthcare infrastructure, high awareness, and the presence of major diagnostic companies. Asia-Pacific is projected to register the fastest CAGR during the forecast period due to rising cancer prevalence, increasing healthcare investments, and growing accessibility to diagnostic technologies in countries like China and India.

Competitive Scenario:

Key players in the Global Lung Cancer Diagnostic Tests Market include Roche Diagnostics, Thermo Fisher Scientific, Illumina, Qiagen, Bio-Rad Laboratories, Siemens Healthineers, GE Healthcare, Guardant Health, Agilent Technologies, and F. Hoffmann-La Roche Ltd. These companies are focusing on strategic partnerships, technological advancements, and product launches to enhance their market presence.

Key Market Developments:

In 2023, Guardant Health launched its new blood-based lung cancer screening test with improved early-stage detection sensitivity.

Roche Diagnostics introduced a CE-marked companion diagnostic test for detecting specific EGFR mutations linked to NSCLC therapies.

In 2024, Thermo Fisher Scientific expanded its oncology diagnostics platform with AI-integrated molecular diagnostic capabilities.

Scope of Work – Global Lung Cancer Diagnostic Tests Market

FAQs:

1. What is the current market size of the Global Lung Cancer Diagnostic Tests Market?

The market was valued at USD 2.9 billion in 2023.

2. What is the major growth driver of the Global Lung Cancer Diagnostic Tests Market?

The rising incidence of lung cancer and technological advancements in diagnostic tools are the major growth drivers.

3. Which is the largest region during the forecast period in the Global Lung Cancer Diagnostic Tests Market?

North America currently holds the largest market share.

4. Which segment accounted for the largest market share in the Global Lung Cancer Diagnostic Tests Market?

Imaging tests accounted for the largest market share in 2023.

5. Who are the key market players in the Global Lung Cancer Diagnostic Tests Market?

Key players include Roche Diagnostics, Thermo Fisher Scientific, Illumina, Qiagen, and Guardant Health.